The purpose of this pilot study is to examine the effects of eight 5-day cycles of
subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of
replication-competent HIV in CD4 cells and on the size of HIV viral reservoir in up to 20
participants with chronically suppressed HIV infection (viral load <50 copies/mL).